SEC Form 4 · accession 0001790340-26-000076
Immuneering Corp · IMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett Matthew Hall
Officer — CHIEF SCIENTIFIC OFFICER
Period of report
Jun 15, 2026
Accepted (ET)
Jun 16, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001790340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Jun 15, 2026 | P | 6,035 | $4.15 | A | 382,531 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.